Novavax
NVAX
81 hedge funds and large institutions have $39.7M invested in Novavax in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 38 increasing their positions, 17 reducing their positions, and 67 closing their positions.
300% more call options, than puts
Call options by funds: $19.7M | Put options by funds: $4.93M
124% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 17
27.14% more ownership
Funds ownership: 1.6% → 28.74% (+27%)
42% less funds holding
Funds holding: 140 → 81 (-59)
49% less capital invested
Capital invested by funds: $77.8M → $39.7M (-$38.2M)
84% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.06M |
| 2 |
BlackRock
New York
|
+$1.81M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$713K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$690K |
| 5 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
+$684K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.21M |
| 2 |
Renaissance Technologies
New York
|
-$1.33M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$1.23M |
| 4 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$847K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$659K |
NVAX Hedge Fund Activity: Q2 2019 in Review
81 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q2 2019, worth a combined $39.7M — down 49% from $77.8M a quarter earlier.
Sellers outnumbered buyers: 67 funds closed out of NVAX and 11 opened new positions — a net loss of 56 holders — while 17 trimmed existing stakes and 38 added.
The largest buyer was Morgan Stanley, adding an estimated $3.06M. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.21M sold.
- 81 institutional investors held Novavax (NVAX) as of Q2 2019, down from 140 in Q1 2019.
- Funds reported $39.7M of Novavax stock for Q2 2019, down 49% quarter-over-quarter.
- 11 funds opened new Novavax positions in Q2 2019 and 67 closed out, a net change of -56 holders.
- The largest Novavax buyer in Q2 2019 was Morgan Stanley, an estimated $3.06M added.
- The largest Novavax seller in Q2 2019 was Citadel Advisors, an estimated $2.21M sold.
Based on aggregated 13F filings for Q2 2019.